Table 1.
Anfibatide pharmacodynamic effects in healthy volunteers.
| Groups | Number/group | Emax (%) Mean ± SD |
Tmax (h) Mean ± SD |
Tmin (h) Mean ± SD |
AUEC (%) Mean ± SD |
|---|---|---|---|---|---|
| Single dose groups | |||||
| 1 (µg/60 kg) | 10 | 79.5 ± 14.2 | 0.201 ± 0.171 | 4.4 ± 1.4 | 149.4 ± 82.9 |
| 1.5 (µg/60 kg) | 10 | 80.7 ± 16.9 | 0.176 ± 0.289 | 4.6 ± 0.8 | 183.4 ± 66.2 |
| 2 (µg/60 kg) | 10 | 89.9 ± 11.9 | 0.085 ± 0.000 | 5.9 ± 0.3 | 231.5 ± 72.5 |
| 3 (µg/60 kg) | 9 | 92.3 ± 9.1 | 0.131 ± 0.138 | 7.1 ± 1.1 | 299.8 ± 70.9 |
| 4 (µg/60 kg) | 10 | 97.8 ± 1.9 | 0.210 ± 0.200 | 8.0 ± 0.0 | 338.9 ± 95.6 |
| 5 (µg/60 kg) | 10 | 96.7 ± 2.4 | 0.210 ± 0.200 | 8.0 ± 0.0 | 324.0 ± 90.8 |
| Multiple dose groups | |||||
| 3 µg/60 kg + CRI at 1.5 h | 6 | 81.3 ± 18.4 | 1.72 ± 2.99 | 27.5 ± 0.0 | 1248.7 ± 236.9 |
| 3 µg/60 kg + CRI | 12 | 82.2 ± 7.1 | 8.03 ± 8.58 | 28 ± 0.0 | 1694.4 ± 214.7 |
| 5 µg/60 kg + CRI | 12 | 94.9 ± 6.7 | 6.69 ± 8.88 | 28 ± 0.0 | 2190.1 ± 303.3 |
CRI, constant rate infusion; Emax, maximal effect on inhibition of ristocetin-induced platelet aggregation; Tmax, time to Emax; Tmin, time of minimal inhibitory effect on platelet aggregation; AUEC, area under the effect curve.